Assessment of Knowledge on Pneumococcal Vaccination Among Diabetologists in India

• Sponsor: M.V. Hospital for Diabetes (Other)
• Overall Status: Not yet recruiting
• CT.gov ID: NCT05721092
• Collaborator: MSD Pharmaceuticals LLC (Industry)
• Enrollment: 100
• Anticipated Duration (Months): 5.3

Study Details

Study Description

Brief Summary

Asia has the highest burden with the largest contribution of pneumonia burden from India. Pneumonia is also observed as 5th leading cause of deaths in India. People with diabetes with uncontrolled glucose are significantly at higher risk of development of pneumonia. Even though, pneumonia is a vaccine-preventable disease, hospitalization for pneumonia of patients with diabetes are rising. Very limited literature is available on the knowledge and practice of pneumonia vaccination among diabetologists and the rate of pneumonia vaccination received by the patients with diabetes. Hence this study aims to assess their knowledge on the same. In addition, this study also aims to identify the real barriers and facilitators of pneumococcal vaccination among diabetologists in India. A cross-sectional study will be conducted among 25diabetologists in each of the four zones in India representing all directions - North, East, West and South. Diabetologists will be selected through purposive sampling. A semi-structured questionnaire (study tool) is designed based on the existing literature that addresses our objectives. An education session on Pneumococcal vaccination will be conducted for the diabetologists through webinar after completing the survey. A post assessment will be done using the same questionnaire among the study participants after the education session in order to see an increase in the knowledge of pneumococcal vaccination.

Condition or Disease	Intervention/Treatment	Phase
Pneumococcal Vaccine	Other: Pre and Post Education on practice of pneumococcal vaccination

Study Design

• Study Type: Observational
• Anticipated Enrollment: 100 participants
• Observational Model: Cohort
• Time Perspective: Cross-Sectional
• Official Title: Assessment of Knowledge, Facilitators and Barriers of Pneumococcal Vaccination: A Cross-sectional Study Among Diabetologists in India
• Anticipated Study Start Date: Feb 20, 2023
• Anticipated Primary Completion Date: Jul 31, 2023
• Anticipated Study Completion Date: Jul 31, 2023

Outcome Measures

Primary Outcome Measures

1. To identify the facilitators and barriers of pneumococcal vaccination among diabetologists in India. [6 months]

Secondary Outcome Measures

1. To assess the knowledge, attitude and practices of pneumococcal vaccination among select diabetologists across India. [6 months]

2. To examine the association of knowledge and practice of vaccination among diabetologists [6 months]

3. To assess the change in the knowledge of pneumococcal vaccination post educational intervention [6 months]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 25 Years to 65 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

Diabetologists willing to participate in the study

Exclusion Criteria:

Unwillingness to give consent for participation

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

• M.V. Hospital for Diabetes
• MSD Pharmaceuticals LLC

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Vijay Viswanathan, Managing Director, M.V. Hospital for Diabetes
• ClinicalTrials.gov Identifier: NCT05721092
• Other Study ID Numbers: 2023_01_MSDMVH
• First Posted: Feb 9, 2023
• Last Update Posted: Feb 15, 2023
• Last Verified: Feb 1, 2023

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Study Results

No Results Posted as of Feb 15, 2023